Maharashtra: Government-Run Blood Banks Slapped Rs 12.72 Lakh In Fines For Neglecting Daily Stock Updates, Reveals RTI Inquiry

Mumbai: The State Blood Transfusion Council imposed a fine of over Rs 12,72,000 on 93 government-run blood banks between December 2022 to April 2023 for not updating the daily blood stock at MahaSBTC and e-raktkosh portal.

The data was revealed through a Right To Information (RTI) filed by activist Chetan Kothari seeking data regarding penalties imposed on blood banks in the last five months. As per the RTI, RN Cooper blood banks tops the list of penalties in terms of violation. Out of a total 121 days, the blood bank has uploaded its blood stock on e-raktkosh only for 25 days.

“The daily stock on e-raktkosh has not been updated 11 times in December 2022, followed by 22 times in January 2023, six times in February, 27 times in March and 30 days in April. All these clearly show that blood banks have not taken GR seriously,” said Kothari.

The public health department had released a government resolution (GR) on December 2 stating that if banks are charging processing fee in excess of the amount stipulated by the National Blood Transfusion Council (NBTC), a penalty of five times the extra processing fee will be levied on the bank.

A senior blood transfusion officer said that often the families of the patients are least aware of the availability of the blood at blood banks. In view of this, the government created the e-blood bank website on which blood banks of all the states have to upload information about their stock. “The basic objective is that whenever a patient needs blood and there is no blood in the blood bank of the hospital, then they can go to thee-blood bank and search in which blood bank the blood is available,” he said.

 

Related Posts

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Piramal, Ajinomoto team on ADC development and manufacturing

Piramal, Ajinomoto team on ADC development and manufacturing

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India